Sequence Bio GTM brain

category

market profile

• text: Genetic evidence can help discovery teams prioritize targets and understand treatment response.
• text: The business combines research participants, clinical collaborators and life sciences partnerships; product and licensing revenue are not publicly specified.

personas

• title: Pharma head of discovery genetics
  pains:

  • Prioritizing targets with insufficient human causal evidence
  • Finding differentiated genetic signals for hard-to-treat diseases
• title: Biopharma business development director
  pains:

  • Finding differentiated external disease biology
  • Structuring research collaborations that can advance into medicines
• title: Clinical and academic genetics investigator
  pains:

  • Recruiting families with inherited disease
  • Connecting family and clinical histories to genetic insights

icp

• text: Life sciences organizations pursuing genetically informed target discovery and therapeutic development; size and geography are not specified.
• text: Newfoundland and Labrador clinical providers and academic research groups studying inherited disease are research partners.

message pillars

• text: Ground better medicines in human genetics.
• text: Use the founder population to focus on genetic disease drivers.
• text: Pair local clinical expertise with life sciences partners.

objections

• objection: Will findings from a founder population generalize?
  response: Review each target's human evidence and a replication plan with the scientists.
• objection: How are community benefits and participant privacy protected?
  response: Review the benefits and royalty agreement and study-specific governance before joining.

competitors

• name: deCODE genetics
  why: Alternative population-genetics research using an Icelandic founder population.
• name: Regeneron Genetics Center
  why: Another human genetics research organization supporting drug discovery.

keywords

• human genetics drug discovery
• genetically validated drug targets
• founder population genomics
• inherited disease genetics
• clinical genomic partnerships
• genetic biomarkers

voice

• Science-led
• Purpose-driven
• Collaborative

signals

• text: A pharma team is expanding human genetic validation of its discovery pipeline.
• text: A research group is launching an inherited disease or family genetics collaboration.

pricing

motion

channels

• research partnerships
• scientific publications

confidence

Founders

• name: Jeremy Grushcow
  title: Founder
  role: Founder
  bio: Ph.D. in Molecular Genetics and Cell Biology (University of Chicago, 2000); J.D. with Honors (University of Chicago Law School, 2003). Previously: CBO, Sequence Bio S19 (Raised >$10m; LOIs signed with Sema4, Helix and Biogen); EVP, Strategic Development, Antibe Therapeutics (International partnerships, public company financings and disclosures; preclinical through Phase 1 for a novel pain therapeutic) Best dog dad ever; 7 out of 10 human dad.
• name: Chris Gardner
  title: Founder
  role: Founder